(1) SELECT-NEXT (who did not adequately respond to treatment with conventional synthetic DMARDs (csDMARDs))

	PE	DVT	MACE	Malig-	Doden	SAE
15mg (221)	0	0	0	0	0	4%
30mg (219)	0	0	1	2	0	3%
Placebo (221)	0	0	0	0	0	2%

https://www.ncbi.nlm.nih.gov/pubmed/29908669

(2) SELECT-BEYOND (who did not adequately respond or were intolerant to treatment with biologic DMARDs (bDMARDs))

	PE	DVT	MACE/CV	Malig-nancies	Doden	SAE
15mg (164) - wk24	4	1	3	2	1	5%
30mg (165) - wk24	2*	0	1	2	1*	7%
Placebo (169) - wk12	0	0	0	1	0	0%

https://acrabstracts.org/abstract/upadacitinib-abt-494-in-patients-with-active-rheumatoid-arthritis-and-inadequate-response-or-intolerance-to-biological-dmards-a-phase-3-randomized-placebo-controlled-double-blind-study-of-a-selec/

(3) SELECT-EARLY (monotherapy treatment compared to MTX who were MTX-naïve)

	PE	DVT	MACE	Malig-nancies	Doden	SAE
15mg (314)	0	0	1*	1*	2*	5%
30mg (317)	0	1	1+1*	0	3*	6%
MTX (314)	1	0	1*	0	1*	4%

https://news.abbvie.com/news/upadacitinib-monotherapy-meets-all-primary-and-ranked-secondary-endpoints-versus-methotrexate-in-phase-3-study-in-rheumatoid-arthritis.htm

(4) SELECT-COMPARE (who are on a stable background of MTX and had an inadequate response)

	PE	DVT	MACE	Malig-nancies	Doden	SAE
15mg (651)	1	1	0	N.B.	0	3,7%
HUMIRA (327)	3	0	2	N.B.	2	4,3%
Placebo (651)	1	0	3	N.B.	2	2,9%

https://news.abbvie.com/news/upadacitinib-meets-all-primary-and-ranked-secondary-endpoints-including-superiority-versus-adalimumab-in-phase-3-study-in-rheumatoid-arthritis.htm

(5) SELECT-MONOTHERAPY (monotherapy treatment compared to MTX who did not adequately respond to treatment with MTX)

	PE	DVT	MACE	Malig-nancies	Doden	SAE
15mg (217)	1	0	1*	N.B.	1*	5%
30mg (215)	0	0	0	N.B.	0	3%
MTX (216)	0	0	0	N.B.	0	3%

https://news.abbvie.com/news/abbvies-upadacitinib-shows-positive-results-as-monotherapy-in-phase-3-rheumatoid-arthritis-study-meeting-all-primary-and-key-secondary-endpoints.htm